BOOST: a phase 3 trial of sorafenib vs. best supportive care in first line treatment of hepatocellular carcinoma in patients with deteriorated liver function-Reference-Cited by-同舟云学术

BOOST: a phase 3 trial of sorafenib vs. best supportive care in first line treatment of hepatocellular carcinoma in patients with deteriorated liver function

Published:2021 Issue: Volume: Page:
ISSN:
Container-title:Hepatoma Research
language:
Short-container-title:HR

Author:

Daniele Gennaro,Schettino Clorinda,Arenare Laura,Bilancia Domenico,Farinati Fabio,Federico Piera,Tamberi Stefano,Crivellari Gino,Barni Sandro,Tortora Raffaella,Izzo Francesco,Frassoldati Antonio,Cavanna Luigi,Mucciarini Claudia,Bolondi Luigi,Dinota Angelo,Pelizzaro Filippo,Piccirillo Maria Carmela,Gargiulo Piera,Di Maio Massimo,Gallo Ciro,Perrone Francesco,Daniele Bruno

Publisher

OAE Publishing Inc.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments;Digestive and Liver Disease;2023-12

2. Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis;Liver Cancer;2023-10-14

3. Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials;Liver Cancer;2023

4. Current landscape and future directions for systemic treatments of hepatocellular carcinoma;Hepatoma Research;2023